Cassava Sciences, Inc. (SAVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SAVA Stock Price Chart Interactive Chart >
SAVA Price/Volume Stats
| Current price | $28.80 | 52-week high | $62.49 |
| Prev. close | $28.00 | 52-week low | $13.84 |
| Day low | $27.30 | Volume | 1,102,900 |
| Day high | $29.09 | Avg. volume | 1,949,419 |
| 50-day MA | $33.47 | Dividend yield | N/A |
| 200-day MA | $29.56 | Market Cap | 1.15B |
Cassava Sciences, Inc. (SAVA) Company Bio
Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.
Latest SAVA News From Around the Web
Below are the latest news stories about CASSAVA SCIENCES INC that investors may wish to consider to help them evaluate SAVA as an investment opportunity.
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall. |
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With InvestorsCassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage. |
Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial ResultsEditor's note: The headline of this story has been updated to more accurately reflect the results of the Cassava Sciences Phase 2 trial for simufilam. Cassava Sciences Inc (NASDAQ: SAVA) announced topline Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. Study participants were administered open-label simufilam tablets 100mg twice daily for one year or more. Endpoints were measured at baseline (study entry) and month 12. In the mild sub-group, ADAS-Cog (cog |
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s DiseaseFigure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point |
Cassava Sciences Stock Shows Big Jump In Its Relative Strength RatingCassava Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 87. |
SAVA Price Returns
| 1-mo | 3.75% |
| 3-mo | -18.34% |
| 6-mo | 64.57% |
| 1-year | -37.02% |
| 3-year | 254.68% |
| 5-year | 357.14% |
| YTD | -2.51% |
| 2022 | -32.40% |
| 2021 | 540.76% |
| 2020 | 31.15% |
| 2019 | 511.76% |
| 2018 | -78.75% |
Loading social stream, please wait...